Titan Biotech Limited approved the issuance of bonus equity shares and an increase in authorized share capital during its Thirty-Fourth Annual General Meeting (AGM) held on September 29, 2026.

The meeting was conducted through Video Conferencing (VC) and Other Audio Visual Means (OAVM) in compliance with SEBI and MCA regulations. A total of 256 members participated, including 10 from the promoter group and 246 public shareholders. No members attended in person or through proxies, reflecting the fully digital nature of the proceedings.

Key resolutions passed

The Board transacted both ordinary and special business items. The ordinary business included the adoption of audited financial statements for FY26 and the declaration of a dividend on equity shares. Directors Supriya Singla and Shivom Singla were re-appointed as directors liable to retire by rotation.

The special business agenda focused on capital structure changes and operational financing:

• Increase in authorized share capital and alteration of the Memorandum of Association.
• Issuance of bonus equity shares to existing members.
• Authorization for loans and borrowing funds.
• Mortgage of company property for borrowing purposes under Section 180(1)(a) of the Companies Act, 2013.
• Ratification of remuneration for the Cost Auditor for FY27.
• Re-appointment of Rohit Jain as Independent Director for a second five-year term starting September 30, 2026.

Voting results and shareholder participation

The Company Secretary disclosed the voting results pursuant to Regulation 44(3) of SEBI Listing Regulations. The total number of shareholders on the record date (September 22, 2026) was 19,666. The total outstanding equity share capital stood at 4,13,18,500 shares.

Voting was conducted via remote e-voting and e-voting at the meeting. The promoter and promoter group held 2,30,47,520 shares, representing approximately 55.78% of the total outstanding capital. Public non-institutional shareholders held 1,82,70,980 shares. Institutional public shareholders held no shares.

All 10 resolutions were passed with requisite majorities. The table below summarizes the voting outcome for key capital-related resolutions:

Note: For resolutions where promoters had an interest (Items 3, 4, 7), specific promoters abstained from voting. Item 7 (Loans) saw lower total votes polled due to multiple promoter abstentions.

Meeting proceedings and attendance

Naresh Kumar Singla, Managing Director, served as the Chairman of the meeting. The quorum was present, and the session commenced at 3:00 pm and concluded at 4:09 pm after allowing 15 minutes for electronic voting.

Key managerial personnel and directors who attended via VC included:

What the numbers show

The voting data reveals a significant concentration of promoter participation relative to total attendance. While 256 members were present, only 10 belonged to the promoter and promoter group category, with the remaining 246 being public shareholders. However, in terms of voting power, the promoter group's holding of 2,30,47,520 shares constituted the majority of votes polled in most resolutions, often exceeding 90% of the total votes cast when they did not have a conflict of interest.

For resolutions where promoters were interested (such as director reappointments), their abstention significantly reduced the total votes polled. For instance, in the reappointment of Ms. Supriya Singla, total votes polled dropped to 2,18,74,959 compared to 2,36,08,850 for non-conflict items like the dividend declaration. This highlights the structural influence of the promoter family in corporate governance decisions.

The simultaneous approval of a bonus issue and an increase in authorized capital indicates a strategic move to expand the company's equity base and financial flexibility without immediate dilution of control, assuming the bonus is issued to existing shareholders. The authorization for loans and property mortgage further signals potential upcoming capital expenditure or working capital needs.

Titan Biotech has published newspaper advertisements confirming the schedule for its 34th Annual General Meeting (AGM). The company notified the BSE on September 7, 2026, regarding these disclosures.

The advertisements were placed in Financial Express and Naya India on September 6, 2026, in English and Hindi respectively. This step ensures compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

AGM Details

The 34th AGM is scheduled to take place on Tuesday, September 29, 2026, at 3:00 pm. The meeting will be conducted through Video Conferencing or Other Audio-Visual Means (VC/OAVM). Shareholders can access the notice and related information on the company’s website.

E-Voting and Record Date

Shareholders eligible as of the record date can cast their votes remotely. The cut-off date for e-voting eligibility is September 22, 2026. The remote e-voting window opens on September 26, 2026, at 10:00 am and closes on September 28, 2026, at 5:00 pm.

Key Dates

Charanjit Singh, Company Secretary and Compliance Officer, confirmed these details in communications to the BSE.